SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company

NEW YORK , July 11, 2022 /PRNewswire/ -- 

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical Company ("La Jolla" or the "Company") (NASDAQ: LJPC) in connection with the proposed acquisition of the Company by Innoviva, Inc. (NASDAQ: INVA) via tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $6.23 in cash for each share of La Jolla common stock owned.  The transaction is valued at approximately $149 million.